Tak Paul Peter 4
4 · Candel Therapeutics, Inc. · Filed Mar 20, 2025
Insider Transaction Report
Form 4
Tak Paul Peter
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-03-19$9.00/sh−400$3,601→ 225,740 total - Sale
Common Stock
2025-03-18$8.77/sh−25,772$226,023→ 226,140 total
Footnotes (3)
- [F1]This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/19/2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.33 to $9.01, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 herein.